Research programme: antibacterials - Arrow Therapeutics

Drug Profile

Research programme: antibacterials - Arrow Therapeutics

Alternative Names: A 11259; A 158; A 161; A 20194; A 762; A 764; A-00000762; A-00026158; A-00026161; Antibacterials research programme - Arrow Therapeutics; Dehydroquinate synthase inhibitors research programme - Arrow Therapeutics; DHQS inhibitors - Arrow Therapeutics; Shikimate kinase inhibitors - Arrow Therapeutics; Type I dehydroquinase inhibitors - Arrow Therapeutics

Latest Information Update: 03 May 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arrow Therapeutics
  • Class
  • Mechanism of Action Dehydroquinate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Gram-positive infections

Most Recent Events

  • 03 May 2004 Discontinued - Preclinical for Gram-positive infections in United Kingdom (unspecified route)
  • 26 Sep 2003 Data presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2003) have been added to the Bacterial Infections antimicrobial activity section
  • 13 Jan 2002 Preclinical development for Gram-positive infections in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top